DOCK11: A Potential Drug Target and Biomarker for T-Cell Dysregulation

Target Name: DOCK11

NCBI ID: G139818

DOCK11

DOCK11: A Potential Drug Target and Biomarker for T-Cell Dysregulation

Introduction

T-cells are a crucial immune cell that play a vital role in fighting off infections and cancer. They are able to recognize and destroy foreign particles, but when they malfunction or are activated in an inappropriate manner, they can cause diseases such as leukemia, lupus, and multiple sclerosis. One of the key processes that regulate T-cell function is cytokinesis, and DOCK11 is a protein that is involved in this process. In this article, we will discuss DOCK11 as a potential drug target and biomarker for T- cell dysregulation.

DOCK11: Structure and Function

DOCK11 is a protein that is expressed in a variety of tissues, including the brain, spleen, and Peyer's patches of the intestine. It is a member of the DOCK family of proteins, which are involved in intracellular signaling pathways. DOCK11 has a unique structure that includes a catalytic domain, a transmembrane region, and an optional N-terminus. The catalytic domain is responsible for catalyzing the formation of the cytokinesis-coupled protein kinase (CK) active site, which is critical for the regulation of cytokinesis.

DOCK11 is involved in the process of cytokinesis by regulating the activity of the cytoskeleton. It plays a key role in the regulation of microtubule dynamics and in the assembly and disassembly of microtubules. DOCK11 has been shown to interact with the protein tubulin 2 ( MTOR), which is a key regulator of cell growth and metabolism.

DOCK11 is also involved in the regulation of cellular signaling pathways, including the T-cell receptor (TCR) signaling pathway. TCR is a protein that is expressed on the surface of T-cells and is involved in the recognition of foreign antigens. DOCK11 has been shown to interact with the T-cell receptor and to regulate the signaling pathway that downstream of the TCR.

DOCK11 as a Potential Drug Target

DOCK11 is a potential drug target because of its involvement in the regulation of cellular signaling pathways. Drugs that target DOCK11 or its downstream targets have been shown to be effective in treating a variety of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

One of the potential mechanisms by which DOCK11 can be targeted is by inhibiting its catalytic activity with small molecules or antibodies. This would prevent DOCK11 from forming the CK active site and would disrupt its ability to regulate cytokinesis.

Another potential mechanism for targeting DOCK11 is by inhibiting its interaction with MTOR. This would prevent DOCK11 from regulating microtubule dynamics and would disrupt its ability to regulate T-cell signaling.

DOCK11 as a Biomarker

DOCK11 can also be used as a biomarker for T-cell dysregulation. DOCK11 is expressed in a variety of tissues and is involved in the regulation of cellular signaling pathways. Therefore, changes in DOCK11 expression levels can provide information about the levels of T-cell dysregulation.

DOCK11 is a protein that is involved in the regulation of cytokinesis, which is a critical process for the development and function of T-cells. Therefore, changes in DOCK11 expression levels can provide information about the levels of T-cell dysfunction and the effectiveness of therapeutic interventions.

Conclusion

In conclusion, DOCK11 is a protein that is involved in the regulation of cytokines

Protein Name: Dedicator Of Cytokinesis 11

Functions: Guanine nucleotide-exchange factor (GEF) that activates CDC42 by exchanging bound GDP for free GTP. Required for marginal zone (MZ) B-cell development, is associated with early bone marrow B-cell development, MZ B-cell formation, MZ B-cell number and marginal metallophilic macrophages morphology. Facilitates filopodia formation through the activation of CDC42

The "DOCK11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DOCK11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets